The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Billion Auto, Inc.; Analysis of Proposed Consent Order to Aid Public Comment; Proposed Consent Agreement
Ramey Motors, Inc.; Analysis of Proposed Consent Order to Aid Public Comment; Proposed Consent Agreement
Sandler, Travis & Rosenberg
Dow Chemical Company, The
The Commission challenged Dow Chemical’s $18.8 billion proposed acquisition of Rohm & Haas Company as anticompetitive in the markets for various acrylics and other industrial chemicals used to make coated paper products, paints, and adhesives. According to the Commission’s complaint, the product markets in question include acrylic monomers, used in goods ranging from hygiene products to paints and industrial coatings, hollow sphere particles, used in paper products, and acrylic latex polymers, used in traffic paints. Given the high concentration in each of the product markets, the proposed acquisition would have represented a merger to monopoly. To remedy its anticompetitive concerns, the Commission required Dow to divest assets to Hager Pacific Acquisitions LLC.
1203002 Informal Interpretation
1203002 Informal Interpretation
20120613: Arlon Food and Agriculture Partners LP; Imperial Sugar Company
20120612: Kelso Investment Associates VIII, L.P.; Quad-C Partners VII, L.P.
20120611: Arlon Food and Agriculture Partners LP; Edward Billington and Son, Limited
20120609: DCP Midstream Partners, LP; Spectra Energy Corp.
20120608: DCP Midstream Partners, LP; ConocoPhillips
20120603: Kellogg Company; The Procter & Gamble Company
20120600: SS&C Technologies Holdings, Inc.; Thomson Reuters Corporation
20120598: Park-Ohio Holdings Corp.; Sun Capital Partners V, L.P.
20120591: Park-Ohio Holdings Corp.; Sun Capital Partners IV, L.P.
1203008 Informal Interpretation
1203008 Informal Interpretation
Healthcare Technology Holdings, Inc., In the Matter of
The FTC reached a settlement with Healthcare Technology Holdings, Inc., the parent company of market research firm IMS Health Inc., according to which IMS has agreed to sell two product lines of rival SDI Health LLC, as a condition of allowing it to proceed with its acquisition of SDI. The proposed settlement order requires the sale of SDI's promotional audit and medical audit businesses to an FTC-approved buyer to resolve the agency's charges that IMS's acquisition of SDI, as originally proposed, is anticompetitive and likely would increase prices for market research products in the health care industry. On1/10/2012, the FTC approved a modified final order settling the charges.